12 SITES  |  554 PATIENTS

The Early neo2 Registry is an investigator-initiated and conducted, single arm, multicenter registry that assessed the ACURATE neo2 Aortic Valve System’s performance.1

 
Echocardiographic images of 85% of the Early neo2 Registry patients were analyzed by an echocardiographic core-lab analysis and presented by Dr. Andreas Rück from the Karolinska Institute (Stockholm, Sweden) at TVT, 2021. View the presentation.2
 

 

 
2.7%

MODERATE OR SEVERE PVL*

 
Hemodynamic
Coronary Access
stroke icon
Complication Rates
 

 

0.0%

CORONARY OBSTRUCTION§

ACURATE neo2 video
 
 

 

 

Percent of evaluable echocardiograms demonstrating post-procedure PVL rates from the core-lab adjudicated Early neo2 Registry.2



Active PVseal: The ACURATE neo2 valve's extended sealing skirt conforms to the native valve annulus.
 
 

A separate videodensitometry angiographic core-lab adjudicated analysis compared patients implanted with the ACURATE neo2 and ACURATE neo™ valves and demonstrated significant aortic regurgitation reduction.1

Percent of evaluable echocardiograms from a separate videodensitometry angiographic core-lab analysis of the Early neo2 Registry outcomes.1,**

ACURATE neo2 Aortic Valve System
** n = 120 Early neo2 Registry patients implanted with ACURATE neo2 (Karolinska University Hospital and Kerkhoff Klinik), n = 108 patients implanted with ACURATE neo (Karolinska University Hospital)
 

 

Clinical performance demonstrated in the Early neo2 Registry core-lab analysis showed optimized ACURATE neo2 Valve performance with a low PVL rate, best-in-class Pacemaker Implantation rate, no coronary obstruction and low overall complications.1,2

 
Top